Harrington Investments INC Sells 257 Shares of Stryker Co. (NYSE:SYK)

Harrington Investments INC trimmed its position in shares of Stryker Co. (NYSE:SYK) by 2.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,641 shares of the medical technology company’s stock after selling 257 shares during the quarter. Stryker makes up 1.7% of Harrington Investments INC’s holdings, making the stock its 17th biggest holding. Harrington Investments INC’s holdings in Stryker were worth $3,111,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in SYK. Clearstead Trust LLC grew its stake in shares of Stryker by 5.1% in the fourth quarter. Clearstead Trust LLC now owns 13,645 shares of the medical technology company’s stock worth $4,913,000 after purchasing an additional 663 shares during the last quarter. Copperwynd Financial LLC lifted its holdings in Stryker by 3.5% during the 4th quarter. Copperwynd Financial LLC now owns 2,362 shares of the medical technology company’s stock worth $851,000 after buying an additional 79 shares during the period. Picton Mahoney Asset Management lifted its holdings in Stryker by 12.1% during the 4th quarter. Picton Mahoney Asset Management now owns 762 shares of the medical technology company’s stock worth $275,000 after buying an additional 82 shares during the period. Associated Banc Corp grew its position in shares of Stryker by 1.4% in the 4th quarter. Associated Banc Corp now owns 20,894 shares of the medical technology company’s stock valued at $7,523,000 after buying an additional 290 shares during the last quarter. Finally, HMV Wealth Advisors LLC acquired a new stake in shares of Stryker in the fourth quarter valued at about $841,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Price Performance

Shares of NYSE SYK opened at $369.96 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The firm’s 50-day simple moving average is $383.04 and its 200 day simple moving average is $373.37. The stock has a market cap of $141.17 billion, a price-to-earnings ratio of 47.68, a PEG ratio of 2.93 and a beta of 0.95. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the company earned $3.46 earnings per share. As a group, research analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date is Monday, March 31st. Stryker’s payout ratio is currently 43.30%.

Wall Street Analyst Weigh In

SYK has been the topic of several analyst reports. Argus set a $450.00 target price on Stryker in a report on Monday, February 3rd. Truist Financial increased their price objective on shares of Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research report on Thursday, January 30th. Barclays boosted their target price on shares of Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Wells Fargo & Company increased their price target on Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Finally, Royal Bank of Canada boosted their price objective on Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research note on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and a consensus price target of $421.90.

Insider Buying and Selling

In other Stryker news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by corporate insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.